SlideShare una empresa de Scribd logo
1 de 74
Descargar para leer sin conexión
PREFORMULATION
PREPARED BY:-
PANDYA DEEP R.
M.PHARM SEM-1
PHARMACEUTICS
Guided By:-
Mr. Keyur Patel
Pharmaceutics Department
K.B.Raval College Of Pharmacy
1
Incompatibility- general aspects
►inactivation of drug through either decomposition or
loss of drug by its conversion to a less favorable
physical or chemical form.
►It affects safety, therapeutic efficacy, appearance or
elegance.
►When we mix two or more API and / or excipient with
each other & if they are antagonistic & affect
adversely the safety, therapeutic efficacy, appearance
or elegance then they are said to be incompatible.
2
Importance of Drug Excipient Compatibility
Study:-
 Stability of the dosage form can be maximized.
 It helps to avoid the surprise problems.
 DECS data is essential for IND (investigational
new drug ) submission.
 Determine a list of excipients that can be
used in final dosage form.
3
 Aspects of above tests are-
►Identification of compatible excipients for a
formulation
►Identification of stable storage conditions for
drug in solid or liquid state.
4
Types Of Incompatibility
 Physical incompatibility:- It involves the change in
the physical form of the formulation which involves
color changes, liquefaction, phase separation or
immiscibility.
 Chemical incompatibility:- It involves undesirable
change in formulation which is due to formation of
new chemical comp. with undesirable activity or our
formulation undergoes hydrolysis, oxidation,
reduction, precipitation, decarboxylation,
racemization.
 Therapeutic incompatibility:- It is type of in vivo
compatibility. 5
 Solid state reactions:
much slower and difficult to interpret.
 Liquid state reactions:
easier to detect - Acc. to Stability Guidelines
by FDA following conditions should be evaluated
for solutions or suspensions .
6
 FOR SOLID STATE REACTIONS:
SampleA: -mixture of drug and excipient
SampleB: -SampleA+ 5% moisture
SampleC: -Drug itself without excipients
7
 All the samples of drug-excipient blends are kept
for 1-3 weeks at specified storage conditions.
 Then sample is physically observed .
 It is then assayed by TLC or HPLC or DSC.
 Whenever feasible, the degradation product are
identified by MASS SPECTROSCOPY, NMR or
other relevant analytical techniques.
8
FOR LIQUID STATE REACTIONS:
 Place the drug in the solution of additives.
 Both flint and amber vials are used.
 This will provide information about
Susceptibility to oxidation. –
Susceptibility to light exposure. –
Susceptibility to heavy metals.
 In case of oral liquids, compatibility with ethanol,
glycerin ,sucrose, preservatives and buffers are
usually carried out. 9
Technique Name
 1) TMA a) DSC
b) DTA
 2) ASS
 3) FT-IR
 4) DRS
 5) Chromatography
 6) Radiolabelled Techniques
 7) Vapour Pressure osmometry
 8) Flourescence Spectroscopy 10
11
KNOWN INCOMPATIBILITIES
Functional group Incompatibility Type of reaction
Primary amine Mono & Di-saccharides Amine-Aldehyde &
Amine-Acetal
Ester, Lactone Basic component Ring opening,
Ester base hydrolysis
Aldehyde Amine, Carbohydrate Aldehyde-Amine, Schiff base
Or Glycosylamine formation
Carboxyl Base Salt formation
Alcohol Oxygen Oxidation to Aldehyde
& Ketones
Sulfhydryl Oxygen Dimerization
Phenol Metal Complexation
Gelatin- Capsule Shell Cationic Surfactant Denaturation 12
1) INTRODUCTION
Thermal method of analysis are group of
techniques in which changes in physical and /or
chemical properties of a substance are
measured as a function of temperature,
while substance is subjected to controlled
temp programme.
13
 Thermal analytical methods can measure the
following physical properties,
 a) WEIGHT LOSS ON DRYING
 b) ENTHALPY
 c) TEMP
 d) GAS EVOLUTION
 e) ELECTRICAL CONDUCTIVITY
 f) OPTICAL CHARACTERISTIC
 g) MAGNETIC PROPERTIES
 h) CHANGES IN FORM IN DIMENSION
 i) VISCOELASTIC PROPERTIES OF
SUBSTANCE
14
 They are unique methods in the field of polymer
analysis & of high value for a solid state analysis.
 They finds wide application in
 Detection of impurity
 Determination of moisture content in any drug substance
or any excipient
 Study of polymorphism
 Characterization of hydrates & solvates
 Degree of Crystallinity
 Study of phase diagram
 Drug excipient compatibility study
 Study of complexation 15
Physical properties Name of technique Instrument used
1) MASS A)THERMOGRAVIMETRY THERMO BALANCE
B)EVOLVED GAS ANALYSIS EVOLVED GAS DETECTOR
2) TEMP DIFFERENTIAL THERMAL
ANALYSIS (DTA)
DTA APPARATUS
3) ENTHALPY DIFFERENTIAL SCANNING
CALORIMETRY (DSC)
DIFFERENTIAL
CALORIMETER
4) MECHANICAL PROPERTIES
(DIMENTION,VISCOELASTIC
PROPERTIES)
A)THERMO MECHANICAL
ANALYSIS
TMA APPRATUS
B)THERMODILATOMETRY DILATOMETER
6) OPTICAL
CHARACTERISTIC
THERMOPTOMETRY
7) MAGNETIC
SUSCEPTIBILITY
THERMOMAGNETOMETRY
8) ELECTRICAL RESISTANCE
OR CONDUCTION
THERMOELECTROMETRY
16
 PRINCIPLE: TG is a technique in which a
change in the weight of a substance is recorded
as a function of temperature or time.
 Instrument: Instrument used for
thermogravimetry is thermobalance
→ Major components of a Thermobalance
 Sample container ,usually shallow platinum
crucible.
 Furnace Assembly
 Automatic recording Balance(Micro balance 17
 Factors affecting Thermogravimetry analysis are
 Heating rate
 atmosphere
 Sample characteristic
18
DATA RECORDED IN FORM OF CURVE KNOWN
AS THERMOGRAM.
THERMOGRAMS CAN BE DIVIDED INTO TWO
PORTIONS:
1) HORIZONTAL PORTION:
INDICATE REGION WHERE
THERE IS NO WEIGHT LOSS.
2) CURVED PORTION: INDICATE REGIONS OF
WEIGHT LOSS.
19
 PRINCIPLE: It is a technique in which the
energy necessary to establish a zero temp
difference between the sample & reference
material is measured as a function of temp.
 Endothermic reaction. E.g. Melting, boiling,
sublimation, vaporization, desolvation.
 Exothermic reaction: E.g crystallization,
degradation, polymerization.
20
DIFFERENTIAL SCANNING
CALORIMETRY (DSC)
 DSC is widely used to measure glass transition temp &
characterization of polymer.
 Glass Transition temp(Tg): Temp at which an
amorphous polymer or an amorphous part of
crystalline polymer goes from hard ,brittle state to
soft,
21
C) DIFFERENTIAL THERMAL ANALYSIS
(DTA)
 PRINCIPLE: A Technique in which the temperature
difference between a substance & a reference material is
measured as a function of temperature, while the substance
& reference are subjected to a controlled temperature
programme.
 The Difference in temperature is called as Differential
temp(∆t) is plotted against temperature or a function of time.
 Physical changes usually result in Endothermic peak
,whereas chemical reactions those of an oxidative nature are
exothermic.
22
MAJOR APPLICATION OF THERMAL
ANALYSIS IN PREFORMULATION
 A) Characterization of hydrates and solvates .
 B) study of polymer
 C) Detection of impurity.
 D) Prediction of stability of drug
 E) Degree of crystallinity
 F). Compatibility study of drug with excipient.
 G) Study of complexes & inclusion compounds.
23
MINOR APPLICATIONS
 - DSC is a valuable tool in choice of suppository
base.
 - In study of polymer composition ,miscibility &
individual characterization.
- Study of tablet coating
- Determinations of melting point. etc
- Determination of moisture content in drug.
- Checking technological quality grade of
disintegrate.
- Study of solid drug dispersion.
- Determination of drying temp. for different
excipients. 24
LIMITATIONS OF THERMAL ANALYSIS
 1) low sensitivity for transitions involving small
energies.
 2) The interpretation of the curves & DSC studies
should always Include several conditions & replicate.
 3) Impurity consisting of molecules of same size,
shape, & character as those of the major component
are not detected by DSC, Because these impurity fit
into the matrix of the major component without
disruption of lattice forming solid solution or inclusion
,such impurity are not detected by DSC.
 4) TGA used to studies hydrates & moisture study is
not always reliable.
25
X-RAY DIFFRACTION IN
PREFORMULATION
 METHOD:- Principle:- «- An x-ray irradiation
produce a highly specific diffraction pattern from
a crystal of material.
 An X-ray diffraction pattern from the crystal is
formed a series of dots of varying intensity with
fixed angular & recorded on photographic film. «-
 It is powerful tool for particle size analysis.
26
FTIR TECHNIQUE:
 It has been used to quantify binary
mixtures of polymorphs.
 In identification of polymorphs , only solid
samples (as mineral oil mulls & KBr pellets)
can be used .
 In solutions polymorphs of a compound have
identical spectra .
 Techniques for solid state stability studies:
 Advantages: - Rapid.
• TECHNIQUE IS QUALITATIVE & QUANTITATIVE. 27
(1) INTRODUCTION
 Impurities in pharmaceuticals are the unwanted
chemicals that remain with active pharmaceutical
ingredients (APIs),or develop during formulation, or
upon aging of APIs and formulated APIs to medicines.
 Webster‘s dictionary defines impurity are something
that is impure or makes something else impure.
.
 ►Organic volatile impurities
OVIs are generally solvents used in the synthesis or
during the formulation of the drug product.
28
 a) impurities associated in with APIs
 b) impurities that forms are created during
formulation & or with aging or that are related to
formulated forms.
 According to ICH guidelines impurities
associated with APIs are classified in to following
categories- (a)Organic impurities
(b)Inorganic impurities
(c)Residual solvents
(d)Other materials 29
Starting materials
Intermediates
Penultimate intermediate(Final
intermediates)
By-products
Interaction products
Related products
Degradation products 30
 INTERNATIONAL CONFERENCE ON HARMONISATION OF
TECHNICAL REQUIREMENT FOR REGISTRATION OF
PHARMACEUTICALS FOR HUMAN USE
 ICH HARMONISED TRIPARTITE GUIDELINE
IMPURITIES:
 GUIDELINE FOR RESIDUAL SOLVENTS
Q3C(R3) Impurities: Guideline for Residual
Solvents Q3C
 Impurities: Guideline for Residual Solvents
(Maintenance) PDE for Tetrahydrofuran (in
Q3C(R3)) Q3C(M) 31
ICH HARMONISED TRIPARTITE
GUIDELINE
 GENERAL PRINCIPLES
Classification of Residual Solvents by Risk Assessment
 The term "tolerable daily intake" (TDI) is used by
the International Program on Chemical Safety (IPCS) to
describe exposure limits of toxic chemicals and "acceptable
daily intake"(ADI) is used by the World Health Organization
(WHO) and other national and international health
authorities and institutes. The new term "permitted daily
exposure" (PDE) is defined in the present guideline as a
pharmaceutically acceptable intake of residual solvents to
avoid confusion of differing values for ADI's of the same
substance.
 Residual solvents assessed in this guideline are listed
in Appendix 1 by common names and structures. They were
evaluated for their possible risk to human health and placed
into one of three classes as follows:
32
CLASSES EVALUATED ON THE BASES OF
THEIR POSSIBLE RISK
 Class 1 solvents: Solvents to be avoided
carcinogens and environmental
e.g.,Benzene, Carben tetrachloride, 1,1-Dichlorobenzene, etc
 Class 2 solvents: Solvents to be limited
Non-genotoxic animal carcinogens or possible causative agents
of other irreversible toxicity such as neurotoxicity or
teratogenicity.
e.g.,Acetonitrile,Chlorobenzene,Chloroform,Cyclohexane
 Class 3 solvents: Solvents with low toxic potential
Solvents with low toxic potential to man;Class 3 solvents have
PDEs of 50 mg or more per day.
e.g.,Acetone, Anisol, 1-Butanol, Cumene, Ethyl ether,etc .
 Class4 solvents: Solvents for which no toxicological data
have been found
Sovents for which no adequate toxicological have been found.
e.g.,1,1-Dietoxypropane,Trifluroacetic acid,Ethyl acetate,etc.
33
METHODS FOR ESTABLISHING
EXPOSURE LIMITS:-
 The Gaylor-Kodell method of risk assessment, is
appropriate for Class 1 carcinogenic solvents. Only in cases
where reliable carcinogenicity data are available should
extrapolation by the use of mathematical models be applied
to setting exposure limits. Exposure limits for Class 1
solvents could be determined with the use of a large safety
factor
 Acceptable exposure levels in this guideline for Class 2
solvents were established by calculation of PDE values.
PDE is derived from the no-observed-effect level (NOEL),
or the lowest-observed effect level (LOEL) in the most
relevant animal study as follows:
 PDE = NOEL x Weight Adjustment
F1x F2 x F3 x F4 x F5
 The PDE is derived preferably from a NOEL. If no
NOEL is obtained, the LOEL may be used.
34
METHODS FOR ESTABLISHING
EXPOSURE LIMITS:-
 F1 = A factor to account for extrapolation between
species, F1 takes into account the comparative
surface area: body weight ratios for the species
concerned and for man.
 F2 = A factor of 10 to account for variability
between individuals.
 F3 = A variable factor to account for toxicity
studies of short-term exposure
 F4 = A factor that may be applied in cases of
severe toxicity, e.g. non-genotoxic carcinogenicity,
neurotoxicity or teratogenicity.
 F5 = A variable factor that may be applied if the
no-effect level was not established 35
LIMITS OF RESIDUAL SOLVENTS :-
 Solvent Concentration Limit (ppm)
 Benzene 2
 Carbon tetrachloride 4
 1,2-Dichloroethane 5
 1,1-Dichloroethene 8
 1,1,1-Trichloroethane 1500
Solvents to Be Avoided:-
36
LIMITS OF RESIDUAL SOLVENTS
Class 2 solvents in pharmaceutical products. .
 SOLVENT CONCENTRATION
LIMIT (PPM)
 Acetonitrile 410
 Chlorobenzene 360
Chloroform 60
 Cyclohexane 3880
 1,2-Dichloroethene 1870
Dichloromethane 600
 N,N-Dimethylacetamide 1090
 N,N-Dimethylformamide 880
 Ethylene glycol 620
 Formamide 220
 Hexane 290
 Methanol 3000
37
LIMITS OF RESIDUAL SOLVENTS
 Acetic acid, Heptane, Acetone,
 Isobutyl acetate, Anisole, Isopropyl acetate,
 1-Butanol, Methyl acetate, 2-Butanol,
 3-Methyl-1-butanol, Butyl acetate, Methylethyl ketone,
 tert-Butylmethyl ether, Methylisobutyl ketone, Cumene,
 2-Methyl-1-propanol, Dimethylsulfoxide, Pentane,
 Ethanol, 1-Pentanol, Ethyl acetate,
1-Propanol, Ethyl ether, 2-Propanol,
Ethyl formate, Propyl acetate Formic acid,
Class 3 solvents which should be limited by GMP or other
quality based requirements.
38
LIMITS OF RESIDUAL SOLVENTS
Solvents for which no adequate toxicological
data was found are given below.
o 1,1-Diethoxypropane,
o Methylisopropyl ketone,
o 1,1-Dimethoxymethane,
o Methyltetrahydrofuran 2,
o 2-Dimethoxypropane,
o Petroleum ether,
o Isooctane,
o Trichloroacetic acid,
o Isopropyl ether
39
AS PER U.S. PHARMACOPOEIA REGULATORY
LIMITS
 Organic volatile USP/NF limits USP/NF 2003
impurities before 2003 (ppm) limits (ppm)
Benzene 100 Not specific
o Chloroform 50 60
o 1,4-Dioxane 100 380
 Methylene chloride 500 600
 Trichloroethylene 100 80
40
PREFORMULATION STUDY OF
BIOTECHNOLOGICAL PRODUCTS
 INTRODUCTION TO BIOTECHNOLOGY
 "Biotechnology means any technological
application that uses biological systems, living
organisms, or derivatives thereof, to make or
modify products or processes for specific use."
41
PHYSICO-CHEMICAL PROPERTIES OF
BIOTECHNOLOGICAL PRODUCTS
 1. Purity, Impurities and Contaminants
 2. Structural Characterization
 3. Conformation Study
 4. Physical Characterization
42
4. PHYSICAL CHARACTERIZATION OF
BIOTECHNOLOGICAL PRODUCTS
 1 SOLID STATE PROPERTIES.
1 Crystallinity
2 Hygroscopicity
3 Molecular weight
4 Thermal Denaturation temperature
5 Extinction coefficient.
 2 SOLUTION PHASE PROPERTIES
1 Ionic Strength
2 pH
3 Adsorption
4 Solubility
5 Surface interaction 43
1. PURITY, IMPURITIES AND
CONTAMINANTS
 The impurities in the products are:
 Process related
cell-culture media, host cell proteins, DNA,
monoclonal antibodies
 Product related
product during the manufacture &/or storage
44
PURITY DETERMINATION
TECHNIQUE
 Protein based product
 SDS-PAGE ,HPLC ,Immunological approaches like
immunoassay
 Amino acid analysis ,N-terminal sequencing ,peptide
mapping
 Pyrogen detection
 Rabbit pyrogen test (exogenous pyrogen) and LAL
Test(endotoxins)
 DNA
 DNA Hybridization studies(dot-blot assay)utilizes
radiolabel led DNA probes
 Microbial
 virus –specific DNA probes , immunoassays.
45
2.STRUCTURAL CHARACTERIZATION
 Protein architecture are typically described in
terms of primary ,secondary ,tertiary &
quaternary & the order of stability is from
primary>>>quaternary.
 Protein structure is determined by following
techniques, SDS-gel electrophoresis ,HPLC
(mainly RP-HPLC) ,Amino acid analysis ,N-
terminal sequencing etc
46
3. CONFORMATION
 A protein’s conformation is the most elusive of its
physical properties in that it may be the most difficult
not only to ascertain but to maintain.
 One must establish the other conformational forms
present have no undesirable chemical, physical and
biological effects.
 It can be determined by the following technique ,X-ray
diffraction ( to study 3Dprotein conformation
,Circular dichrosim ,Peptide mapping ,N-terminal
sequencing or amino acid to determine amino acid
sequence. ,Spectroscopic techniques ( UV,IR, Raman,
Fluorescence)
47
4. PHYSICAL CHARACTERIZATION
SOLID STATE PROPERTIES
 Crystallinity:
 Lack of crystallinity is characterized by the low intensity
peaks or broad bands in the
 POWDER X-ray pattern.
 Other methods used are X-ray Diffraction pattern, Solid
state NMR (SS-NMR),Differential scanning calorimetry (
DSC), Thermo gravimetric analysis (TGA).
 Hygroscopicity:
 The changing environmental conditions can affect the
stability of the hygroscopic products .The estimation of
water content done by the HPLC method 48
4. PHYSICAL CHARACTERIZATION
Molecular weight:
 The molecular size of peptides and proteins are 1 to 3
orders of magnitude larger than that of conventional
drug molecules, is a major factor limiting their
diffusion across the biological membranes.
 Biopharmaceuticals molecular weight ranges from
600 to more than 10,000daltons in their non-
aggregated state
 Larger the size ,lower the permeation across
biological membranes g.i.t, ocular epithelium
,stratum corneum considered as impermeable barriers
to the permeation to the latter.
 Molecular size also restricts diffusion of the
biopharmaceutical across the polymeric barriers, used
in the fabrication of proteins and peptides delivery
systems. 49
4. PHYSICAL CHARACTERIZATION
Extinction coefficient (molar absorptivity):
 For quantification purpose, it is desirable to
measure at a particular UV-VIS wavelength for the
measurement of the protein content.
Thermal denaturation temperature:
 Most proteins can be reversibly denatured with an
increase in temperature and continued increase can
result in irreversible denaturation (seen in enzymes).
 Also in some case, protein unfolds and refolds into new
structure different then original native one.
 FREEZE –DRYING of proteins in presence of
appropriate buffer excipients can minimize the
problem
50
4. PHYSICAL CHARACTERIZATION
SOLUTION PHASE PROPERTIES
Adsorption:
 In the case of where adsorption is due to ionic
interaction of the peptide with the silanol groups on
the glass surface, can be prevented by silylating
the glass (flasks, syringes,etc) with organosilanes
such as Prosil 28.
Solubility and charge:
 The solubility of a protein is a useful indicator of
changes that may occur in the protein conformation
 If a protein denatures, more hydrophobic groups may
be exposed to the aqueous phase from the interior of
the protein.
51
4. PHYSICAL CHARACTERIZATION
PH:
 Ph has profound effect on protein stability ,folding and rates of
reaction which chemically alter the amino acid residues
 In some cases it may be possible to formulate the protein
under conditions where chemical modifications and proteolysis
are minimized as much as possible while maintaining the
protein in misfolded conformation which is readily and rapidly
refolded to “native” form upon administration.
Ionic strength:
 The concentration of counter ions is known to be an important
property in mediating electrostatic interactions in molecule,
and have large effect on stability of a protein as well as its
solubility.
 For example: Guanidium HCl is a strong naturant of protein
where as Guanidium sulphate at equivalent concentration can
stabilize proteins. 52
BIOLOGICAL
CHARACTERIZATION
 Validated biological assays should be performed at the
preformulation stage to assess the biological activity.
 For the complex molecules, the physio-chemical information may
be extensive but unable to confirm the higher order structures, a
biologic activity with a specific quantitative measure.
 Radio receptor assays (RIA) may be used to relate binding of a
protein hormone to a cellular receptor and may be used to asses
activity protein fragments, produced by the enzymatic degradation
 Immunogenicity is ability to induce the formation of antibodies when
combined with antigenicity is the ability to react with specific
antibodies can potentially result in the development of
hypersensitivity reactions.
 Techniques for minimizing the immunogenicity (considered at the
preformulation stage )
1. Cloned peptides and proteins
2. Conjugation of peptides and proteins to low molecular
weight compounds
3. Conjugation of peptides and proteins to various polymers
such as dextran, albumin, dl- amino acids, poly vinyl
pyrrolidone, polyethylene glycol,etc
53
ORAL DELIVERY OF INSULIN BY
CONJUGATION WITH VITAMIN B12
 Limitation of oral delivery of insulin:
1. Proteolysis in GIT
2. Absorption at intestinal entrocyte
 To overcome this problem, we decided to use the
dietary uptake pathway of vitamin B12. Mammals
have an active transport mechanism in the GIT for
the absorption and the cellular uptake of relatively
large vitamin B12. 54
DEGRADATION PROCESSES OF
PROTEIN PHARMACEUTICALS
 PHYSICAL INSTABILITY
1 Denaturation
2 Surface adsorption
3 Aggregation
4 Precipitation.
 CHEMICAL INSTABILITY
1 Hydrolysis
1.1 Deamidation
1.2 Intramolecular aminolysis
1.3 Transpeptidation
2 Oxidation
3 Racemization
4 β-elimination
55
METHODS TO IMPROVE
PHYSICAL STABILITY
 Additives such as metal ions ,polyalcohol
,surfactants ,reducing agents ,chelating agents
and other proteins ,amino acids ,fatty acids and
phospholipids
 Specific ion binding sites can be introduced on
protein molecules in relation to the aggregation and
precipitation. eg salts
 Both ionic and non-ionic surfactants can stabilize
proteins by preventing adsorption of proteins at
interfaces
 At low concentration in aqueous solutions
,polyhydric alcohol such as glycerol by selective
salvation .(excluding the water molecules) 56
METHODS TO IMPROVE CHEMICAL
STABILITY:
 1. Chemical modification of protein molecules:
Synthetic polymers like PEG and Polyoxyethylene
can be coupled to protein molecules chemically to
enhance the chemical stability. Comparatively, lipids
coupled with Insulin can increase the absorption of
Insulin and hence can increase the activity.
 2 Site directed mutagenesis:
This technique creates specific mutations that
alter the amino acid sequence of proteins and create
new proteins.
57
METHODS TO IMPROVE CHEMICAL
STABILITY:
 3. Appropriate choice of conditions:
 pH,
 temperature,
 preservative
 ionic strength. 58
FORMULATION APPROACHES TO
PROTEIN STABILIZATION
Protein stabilization in solution using additives:
 Concentration of salts has profound effect on protein
solution and aggregation.
 Non ionic surfactants like, polysorbate 80 inhibits
protein aggregation because of greater tendency of
surfactant molecule to align themselves at the liquid-air
interface, so, excluding the proteins from interface and
inhibiting surface denaturation.
 Use of cyclodextrin or 2-Hydroxy propyl--cyclodextrin
solubilizes ovine growth hormone and prevents shaking
induced precipitation.
59
FORMULATION APPROACHES TO
PROTEIN STABILIZATION
2. Protein stabilization in the dried solid state:
Lyophilization and spray drying used to dehydrate
heat sensitive molecules and thereby inhibit the
degradative reactions that may be observed when
proteins are formulated in solution
 Mechanism for Stabilization of Dried Proteins:
 Binding of additives to the dried protein to act as a
“water substitute” after removal of hydration shell. As
water substitutes, sugars such as lactose can serve to
partially satisfy Hydrogen bonding requirements of
polar groups in dried proteins.
60
FORMULATION APPROACHES TO
PROTEIN STABILIZATION
 Lyophilization and protein formulation development:
 It is characterized by two primary concerns:
 1 Excipient selection to optimize long term stability of protein in the
dried state.
 2. Effect of excipient on processing parameters of Lyophilization cycle
such as maximum and minimum drying temperature and cycle length and on
the appearance of the lyophilized powder cake.
 Freezing causes gradual concentration of solutes surrounding the protein
molecule s water is removed by the phase change.
 Spray drying of protein pharmaceuticals:
 It is alternative to freeze drying proteins as a process capable of drying
thermally labile materials.
 The particles are dried in the air stream in seconds, owing to high surface
area contact with drying gas.
 Its major advantage over Lyophilization is particle size and shape of final
dried powder. 61
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
 1 Preamble
 The applicant should develop the proper supporting
stability data for biotechnological product and
consider many external conditions that can affect the
product's potency, purity, and quality.
 The purpose of this document is to give guidance to
applicants regarding the type of stability studies that
should be provided in support of marketing
applications.
62
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
 2 Scope of the annex
 Stability Testing of New Drug Substances and
Products'' applies to well-characterized proteins
and polypeptides, their derivatives and products
of which they are components, and which are
isolated from tissues, body fluids, cell cultures, or
produced using recombinant deoxyribonucleic
acid (r-DNA) technology.
 The document does not cover antibiotics,
allergenic extracts, heparins, vitamins, whole
blood, or cellular blood components.
63
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
3 Selection of Batches
 3.1 Drug Substance (Bulk Material)
Where bulk material is to be stored after manufacture, but
before formulation and final manufacturing, stability data
should be provided on at least three batches for which
manufacture and storage are representative of the
manufacturing scale of production.
 3.2 Sample Selection
Where one product is distributed in batches differing in fill
volume (e.g., 1 milliliter (mL), 2 mL, or 10 mL), unit age
(e.g., 10 units, 20 units, or 50 units), or mass (e.g., 1
milligram (mg), 2mg, or 5 mg), samples to be entered into
the stability program may be selected on the basis of a
matrix system and/or by bracketing.
64
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
4. Stability-Indicating Profile
 Consequently, the manufacturer should propose a stability-
indicating profile that provides assurance that changes in
the identity, purity, and potency of the product will be
detected.
 At the time of submission, applicants should have validated
the methods that comprise the stability-indicating profile,
and the data should be available for review.
 The determination of which tests should be included will be
product-specific.
 4.1 Protocol
 The protocol should include all necessary information that
demonstrates the stability of the biotechnological product
throughout the proposed expiration dating period
including, for example, well-defined specifications and test
intervals.
65
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
 4.2 Potency
 For the purpose of stability testing of the
products described in this guideline, potency is
the specific ability or capacity of a product to
achieve its intended effect and is determined by a
suitable in vivo or in vitro quantitative method.
 For that purpose, a reference material calibrated
directly or indirectly against the corresponding
national or international reference material
should be included in the assay.
66
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
5. Storage Conditions
Temperature
 As most finished biotechnological products need
precisely defined storage temperatures, the storage
conditions for the real-time/real-temperature stability
studies may be confined to the proposed storage
temperature.
Humidity
 Biotechnological products are generally distributed in
containers protecting them against humidity.
Therefore, where it can be demonstrated that the
proposed containers (and conditions of storage) afford
sufficient protection against high and low humidity,
stability tests at different relative humidity can
usually be omitted.
67
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
Accelerated and Stress Conditions
 The expiration dating should be based on real-
time/real-temperature data. However it is strongly
suggested that studies be conducted on the drug
substance under accelerated and stress conditions.
 Also useful in determining whether accidental
exposures to conditions other than those proposed
(e.g., during transportation) are deleterious to the
product and also for evaluating which specific test
parameters may be the best indicators of product
stability.
 Light 68
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
Container/Closure
 Stability studies should include samples maintained in the
inverted or horizontal position (i.e., in contact with the
closure), as well as in the upright position, to determine the
effects of the closure on product quality.
 The applicant should demonstrate that the closure used
with a multiple-dose vial is capable of withstanding the
conditions of repeated insertions and withdrawals so that
the product retains its full potency, purity, and quality for
the maximum period specified in the instructions-for-use
on containers, packages, and/or package inserts.
Stability after Reconstitution of Freeze-Dried Product
 The stability of freeze-dried products after their
reconstitution should be demonstrated for the conditions
and the maximum storage period specified on containers,
packages, and/or package inserts. 69
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
6. Testing Frequency
 The shelf lives of biotechnological products may vary
from days to several years.
 With only a few exceptions, however, the shelf lives
for existing products and potential future products
will be within the range of 0.5 to 5 years.
 When shelf lives of 1 year or less are proposed, the
real-time stability studies should be conducted
monthly for the first 3 months and at 3 month
intervals thereafter.
 For products with proposed shelf lives of greater than
1 year, the studies should be conducted every 3
months during the first year of storage, every 6
months during the second year, and year of storage,
every 6 months during the second year, and annually
thereafter. 70
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
7. Specification:
 Although biotechnological products may be
subject to significant losses of activity,
physicochemical changes, or degradation during
storage, international and national regulations
have provided little guidance with respect to
distinct release and end of shelf life
specifications.
 Recommendations for maximum acceptable
losses of activity, limits for physicochemical
changes, or degradation during the proposed
shelf life have not been developed for individual
types or groups of biotechnological products but
are considered on a case-by-case basis.
71
GUIDELINES ON THE STABILITY OF
THE BIOTECHNOLOGICAL PRODUCT
8. Labeling
 For most biotechnological drug substances and
drug products, precisely defined storage
temperatures are recommended.
 Specific recommendations should be stated,
particularly for drug substances and drug
products that cannot tolerate freezing.
 These conditions, and where appropriate,
recommendations for protection against light
and/or humidity, should appear on containers,
packages, and/or package inserts.
72
QUE.
 a) A Pharmacist wants to develop a transdermal
patch of hormone. ,What test should be carried out in
order to ascertain drug-excipient incompatibility?
Give outline and significance of each test.
 Discuss the considerations of OVIs in preform
 Give an applications of Differential scanning
calorimetry and FTIR in preformulation studyulation
study.
 Why OVIs are considered in preformulation
study?
 How the preformulation studies for biotechnologically
derived products are carried out?
73
74

Más contenido relacionado

La actualidad más candente

Compaction profiles
Compaction profilesCompaction profiles
Compaction profilesSiddu K M
 
Drug excipients interaction : Types and techniques
Drug excipients interaction : Types and techniquesDrug excipients interaction : Types and techniques
Drug excipients interaction : Types and techniquesHemant Khandoliya
 
Kinetics of Stability & Stability Testing
Kinetics of Stability & Stability Testing Kinetics of Stability & Stability Testing
Kinetics of Stability & Stability Testing Sidharth Mehta
 
Preformulation stability study
Preformulation stability studyPreformulation stability study
Preformulation stability studyArabinda Changmai
 
Dissolution f1 and f2 Analysis and IVIVC
Dissolution f1 and f2 Analysis and IVIVCDissolution f1 and f2 Analysis and IVIVC
Dissolution f1 and f2 Analysis and IVIVCCipla Pharmaceuticals
 
Comparision of dissolution profile
Comparision of dissolution profileComparision of dissolution profile
Comparision of dissolution profileRanjith Karanam
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient CompatibilitySuraj Choudhary
 
Study of consolidation parameters
Study of consolidation parametersStudy of consolidation parameters
Study of consolidation parametersMehak AggarwAl
 
Pharmaceuticals Dispersion theory- Suspension and Emulsion
Pharmaceuticals Dispersion theory-  Suspension and EmulsionPharmaceuticals Dispersion theory-  Suspension and Emulsion
Pharmaceuticals Dispersion theory- Suspension and EmulsionSachin Aryal
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Naveen Balaji
 
Optimization techniques in pharmaceutical formulation and processing
Optimization techniques in pharmaceutical formulation and processingOptimization techniques in pharmaceutical formulation and processing
Optimization techniques in pharmaceutical formulation and processingReshma Fathima .K
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
 
Compendial methods of dissolution
Compendial methods of dissolutionCompendial methods of dissolution
Compendial methods of dissolutionHemanth KG
 
Study of consolidation parameters
Study of consolidation parametersStudy of consolidation parameters
Study of consolidation parametersayesha samreen
 
Sustained and controlled release drug delivery system
Sustained and controlled release drug delivery systemSustained and controlled release drug delivery system
Sustained and controlled release drug delivery systemParul Sharma
 

La actualidad más candente (20)

Compaction profiles
Compaction profilesCompaction profiles
Compaction profiles
 
Drug excipients interaction : Types and techniques
Drug excipients interaction : Types and techniquesDrug excipients interaction : Types and techniques
Drug excipients interaction : Types and techniques
 
Kinetics of Stability & Stability Testing
Kinetics of Stability & Stability Testing Kinetics of Stability & Stability Testing
Kinetics of Stability & Stability Testing
 
Preformulation stability study
Preformulation stability studyPreformulation stability study
Preformulation stability study
 
co-processed excipients ppt
co-processed excipients pptco-processed excipients ppt
co-processed excipients ppt
 
Dissolution f1 and f2 Analysis and IVIVC
Dissolution f1 and f2 Analysis and IVIVCDissolution f1 and f2 Analysis and IVIVC
Dissolution f1 and f2 Analysis and IVIVC
 
Comparision of dissolution profile
Comparision of dissolution profileComparision of dissolution profile
Comparision of dissolution profile
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient Compatibility
 
Preformulation concept
Preformulation conceptPreformulation concept
Preformulation concept
 
Physics of tablet compression
Physics of tablet compressionPhysics of tablet compression
Physics of tablet compression
 
1. preformulation
1. preformulation1. preformulation
1. preformulation
 
Study of consolidation parameters
Study of consolidation parametersStudy of consolidation parameters
Study of consolidation parameters
 
Pharmaceuticals Dispersion theory- Suspension and Emulsion
Pharmaceuticals Dispersion theory-  Suspension and EmulsionPharmaceuticals Dispersion theory-  Suspension and Emulsion
Pharmaceuticals Dispersion theory- Suspension and Emulsion
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
 
Optimization techniques in pharmaceutical formulation and processing
Optimization techniques in pharmaceutical formulation and processingOptimization techniques in pharmaceutical formulation and processing
Optimization techniques in pharmaceutical formulation and processing
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
 
Compendial methods of dissolution
Compendial methods of dissolutionCompendial methods of dissolution
Compendial methods of dissolution
 
Heckel Plots for Tablet Compression
Heckel Plots for Tablet CompressionHeckel Plots for Tablet Compression
Heckel Plots for Tablet Compression
 
Study of consolidation parameters
Study of consolidation parametersStudy of consolidation parameters
Study of consolidation parameters
 
Sustained and controlled release drug delivery system
Sustained and controlled release drug delivery systemSustained and controlled release drug delivery system
Sustained and controlled release drug delivery system
 

Destacado

Seminar on Preformulation studies
Seminar on Preformulation studiesSeminar on Preformulation studies
Seminar on Preformulation studiesKULDIP DEKA
 
Preformulation
PreformulationPreformulation
Preformulationlahari522
 
Preformulation studies for bulk characterization
Preformulation studies for bulk characterizationPreformulation studies for bulk characterization
Preformulation studies for bulk characterizationmangu3107
 
Formulation and evaluation_of_microspheres[1]
Formulation and evaluation_of_microspheres[1]Formulation and evaluation_of_microspheres[1]
Formulation and evaluation_of_microspheres[1]Dadhichi Thakkar
 
solubility & Pka presentation
solubility & Pka presentationsolubility & Pka presentation
solubility & Pka presentationMayuri Sawant
 
Pharmaceutical aerosols
Pharmaceutical aerosolsPharmaceutical aerosols
Pharmaceutical aerosolsShivaram
 
Quality control tests for tablets
Quality control tests for tabletsQuality control tests for tablets
Quality control tests for tabletsDr. Raja Abhilash
 

Destacado (10)

Seminar on Preformulation studies
Seminar on Preformulation studiesSeminar on Preformulation studies
Seminar on Preformulation studies
 
preformulation
preformulationpreformulation
preformulation
 
Preformulation
PreformulationPreformulation
Preformulation
 
Preformulation
PreformulationPreformulation
Preformulation
 
Preformulation studies for bulk characterization
Preformulation studies for bulk characterizationPreformulation studies for bulk characterization
Preformulation studies for bulk characterization
 
Formulation and evaluation_of_microspheres[1]
Formulation and evaluation_of_microspheres[1]Formulation and evaluation_of_microspheres[1]
Formulation and evaluation_of_microspheres[1]
 
Preformulation
PreformulationPreformulation
Preformulation
 
solubility & Pka presentation
solubility & Pka presentationsolubility & Pka presentation
solubility & Pka presentation
 
Pharmaceutical aerosols
Pharmaceutical aerosolsPharmaceutical aerosols
Pharmaceutical aerosols
 
Quality control tests for tablets
Quality control tests for tabletsQuality control tests for tablets
Quality control tests for tablets
 

Similar a PREFORMULATION

1.preformulation concept in Modern pharmaceutics.pptx
1.preformulation concept in Modern pharmaceutics.pptx1.preformulation concept in Modern pharmaceutics.pptx
1.preformulation concept in Modern pharmaceutics.pptxPNMallikarjun
 
Principle and application of dsc,dta,ftir and x ray diffraction
Principle and application of dsc,dta,ftir and x ray diffractionPrinciple and application of dsc,dta,ftir and x ray diffraction
Principle and application of dsc,dta,ftir and x ray diffractionBhavesh Maktarpara
 
Analytical tech in pre formulation 112070804009
Analytical tech in pre formulation 112070804009Analytical tech in pre formulation 112070804009
Analytical tech in pre formulation 112070804009Patel Parth
 
Drug excipient compatibility
Drug excipient compatibilityDrug excipient compatibility
Drug excipient compatibilityPATEL NISARG
 
preformulation concepts, drug excipient interactions different methods slide...
preformulation concepts, drug excipient interactions  different methods slide...preformulation concepts, drug excipient interactions  different methods slide...
preformulation concepts, drug excipient interactions different methods slide...vamshipradeep
 
Ppt 1 introduction to analysis
Ppt   1 introduction to analysis Ppt   1 introduction to analysis
Ppt 1 introduction to analysis ASHWINI SHELKE
 
Drug.excipient.compatibility
Drug.excipient.compatibilityDrug.excipient.compatibility
Drug.excipient.compatibilityceutics1315
 
Detection identification characterization of degraded products
Detection identification characterization of degraded productsDetection identification characterization of degraded products
Detection identification characterization of degraded productsGnanabhaskar Danaboina
 
Routes of drug degradation
Routes of drug degradationRoutes of drug degradation
Routes of drug degradationAdityaSingh1803
 
Seminar on solid state stability and shelf life by ranjeet singh
Seminar on solid state stability and shelf life by ranjeet singhSeminar on solid state stability and shelf life by ranjeet singh
Seminar on solid state stability and shelf life by ranjeet singhRanjeet Singh
 
ACCELERATED STABILITY STUDY
 ACCELERATED STABILITY STUDY ACCELERATED STABILITY STUDY
ACCELERATED STABILITY STUDYPratikkumarjain
 
Analytical Method Development and Validation of Prednisolone Sodium Phosphate...
Analytical Method Development and Validation of Prednisolone Sodium Phosphate...Analytical Method Development and Validation of Prednisolone Sodium Phosphate...
Analytical Method Development and Validation of Prednisolone Sodium Phosphate...iosrjce
 
Kinetics and Stability testing.pptx
Kinetics and Stability testing.pptxKinetics and Stability testing.pptx
Kinetics and Stability testing.pptxShubhamDeore24
 
Impurity and food agents.seminar.pptx
Impurity and food agents.seminar.pptxImpurity and food agents.seminar.pptx
Impurity and food agents.seminar.pptxAsif Shaikh
 
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...Kamel Mansouri
 

Similar a PREFORMULATION (20)

1.preformulation concept in Modern pharmaceutics.pptx
1.preformulation concept in Modern pharmaceutics.pptx1.preformulation concept in Modern pharmaceutics.pptx
1.preformulation concept in Modern pharmaceutics.pptx
 
Principle and application of dsc,dta,ftir and x ray diffraction
Principle and application of dsc,dta,ftir and x ray diffractionPrinciple and application of dsc,dta,ftir and x ray diffraction
Principle and application of dsc,dta,ftir and x ray diffraction
 
Analytical tech in pre formulation 112070804009
Analytical tech in pre formulation 112070804009Analytical tech in pre formulation 112070804009
Analytical tech in pre formulation 112070804009
 
Drug excipient compatibility
Drug excipient compatibilityDrug excipient compatibility
Drug excipient compatibility
 
preformulation concepts, drug excipient interactions different methods slide...
preformulation concepts, drug excipient interactions  different methods slide...preformulation concepts, drug excipient interactions  different methods slide...
preformulation concepts, drug excipient interactions different methods slide...
 
POSTER FORMAT (1).pptx
POSTER FORMAT (1).pptxPOSTER FORMAT (1).pptx
POSTER FORMAT (1).pptx
 
Ppt 1 introduction to analysis
Ppt   1 introduction to analysis Ppt   1 introduction to analysis
Ppt 1 introduction to analysis
 
Drug.excipient.compatibility
Drug.excipient.compatibilityDrug.excipient.compatibility
Drug.excipient.compatibility
 
Drug.excipient.compatibility
Drug.excipient.compatibilityDrug.excipient.compatibility
Drug.excipient.compatibility
 
Bppk ppt
Bppk pptBppk ppt
Bppk ppt
 
Detection identification characterization of degraded products
Detection identification characterization of degraded productsDetection identification characterization of degraded products
Detection identification characterization of degraded products
 
ICH
ICH ICH
ICH
 
Routes of drug degradation
Routes of drug degradationRoutes of drug degradation
Routes of drug degradation
 
Seminar on solid state stability and shelf life by ranjeet singh
Seminar on solid state stability and shelf life by ranjeet singhSeminar on solid state stability and shelf life by ranjeet singh
Seminar on solid state stability and shelf life by ranjeet singh
 
ACCELERATED STABILITY STUDY
 ACCELERATED STABILITY STUDY ACCELERATED STABILITY STUDY
ACCELERATED STABILITY STUDY
 
Analytical Method Development and Validation of Prednisolone Sodium Phosphate...
Analytical Method Development and Validation of Prednisolone Sodium Phosphate...Analytical Method Development and Validation of Prednisolone Sodium Phosphate...
Analytical Method Development and Validation of Prednisolone Sodium Phosphate...
 
Kinetics and Stability testing.pptx
Kinetics and Stability testing.pptxKinetics and Stability testing.pptx
Kinetics and Stability testing.pptx
 
Chanduppt2
Chanduppt2Chanduppt2
Chanduppt2
 
Impurity and food agents.seminar.pptx
Impurity and food agents.seminar.pptxImpurity and food agents.seminar.pptx
Impurity and food agents.seminar.pptx
 
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
EDSP Prioritization: Collaborative Estrogen Receptor Activity Prediction Proj...
 

Último

biosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibioticsbiosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibioticsSafaFallah
 
Applied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docxApplied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docxmarwaahmad357
 
Alternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabusAlternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabusPradnya Wadekar
 
SUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdf
SUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdfSUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdf
SUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdfsantiagojoderickdoma
 
Shiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky Way
Shiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky WayShiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky Way
Shiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky WaySérgio Sacani
 
Krishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्रKrishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्रKrashi Coaching
 
Application of Foraminiferal Ecology- Rahul.pptx
Application of Foraminiferal Ecology- Rahul.pptxApplication of Foraminiferal Ecology- Rahul.pptx
Application of Foraminiferal Ecology- Rahul.pptxRahulVishwakarma71547
 
MARKER ASSISTED SELECTION IN CROP IMPROVEMENT
MARKER ASSISTED SELECTION IN CROP IMPROVEMENTMARKER ASSISTED SELECTION IN CROP IMPROVEMENT
MARKER ASSISTED SELECTION IN CROP IMPROVEMENTjipexe1248
 
CW marking grid Analytical BS - M Ahmad.docx
CW  marking grid Analytical BS - M Ahmad.docxCW  marking grid Analytical BS - M Ahmad.docx
CW marking grid Analytical BS - M Ahmad.docxmarwaahmad357
 
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...marwaahmad357
 
THE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptx
THE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptxTHE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptx
THE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptxAkinrotimiOluwadunsi
 
PSP3 employability assessment form .docx
PSP3 employability assessment form .docxPSP3 employability assessment form .docx
PSP3 employability assessment form .docxmarwaahmad357
 
KeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceKeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceLayne Sadler
 
Controlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform EnvironmentControlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform EnvironmentRahulVishwakarma71547
 
Lehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.pptLehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.pptSachin Teotia
 
World Water Day 22 March 2024 - kiyorndlab
World Water Day 22 March 2024 - kiyorndlabWorld Water Day 22 March 2024 - kiyorndlab
World Water Day 22 March 2024 - kiyorndlabkiyorndlab
 
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptxQ3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptxArdeniel
 
geometric quantization on coadjoint orbits
geometric quantization on coadjoint orbitsgeometric quantization on coadjoint orbits
geometric quantization on coadjoint orbitsHassan Jolany
 

Último (20)

biosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibioticsbiosynthesis of the cell wall and antibiotics
biosynthesis of the cell wall and antibiotics
 
Applied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docxApplied Biochemistry feedback_M Ahwad 2023.docx
Applied Biochemistry feedback_M Ahwad 2023.docx
 
Alternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabusAlternative system of medicine herbal drug technology syllabus
Alternative system of medicine herbal drug technology syllabus
 
SUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdf
SUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdfSUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdf
SUKDANAN DIAGNOSTIC TEST IN PHYSICAL SCIENCE ANSWER KEYY.pdf
 
Shiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky Way
Shiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky WayShiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky Way
Shiva and Shakti: Presumed Proto-Galactic Fragments in the Inner Milky Way
 
Krishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्रKrishi Vigyan Kendras - कृषि विज्ञान केंद्र
Krishi Vigyan Kendras - कृषि विज्ञान केंद्र
 
Application of Foraminiferal Ecology- Rahul.pptx
Application of Foraminiferal Ecology- Rahul.pptxApplication of Foraminiferal Ecology- Rahul.pptx
Application of Foraminiferal Ecology- Rahul.pptx
 
MARKER ASSISTED SELECTION IN CROP IMPROVEMENT
MARKER ASSISTED SELECTION IN CROP IMPROVEMENTMARKER ASSISTED SELECTION IN CROP IMPROVEMENT
MARKER ASSISTED SELECTION IN CROP IMPROVEMENT
 
CW marking grid Analytical BS - M Ahmad.docx
CW  marking grid Analytical BS - M Ahmad.docxCW  marking grid Analytical BS - M Ahmad.docx
CW marking grid Analytical BS - M Ahmad.docx
 
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
001 Case Study - Submission Point_c1051231_attempt_2023-11-23-14-08-42_ABS CW...
 
THE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptx
THE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptxTHE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptx
THE HISTOLOGY OF THE CARDIOVASCULAR SYSTEM 2024.pptx
 
PSP3 employability assessment form .docx
PSP3 employability assessment form .docxPSP3 employability assessment form .docx
PSP3 employability assessment form .docx
 
KeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data scienceKeyBio pipeline for bioinformatics and data science
KeyBio pipeline for bioinformatics and data science
 
Controlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform EnvironmentControlling Parameters of Carbonate platform Environment
Controlling Parameters of Carbonate platform Environment
 
Cheminformatics tools supporting dissemination of data associated with US EPA...
Cheminformatics tools supporting dissemination of data associated with US EPA...Cheminformatics tools supporting dissemination of data associated with US EPA...
Cheminformatics tools supporting dissemination of data associated with US EPA...
 
Lehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.pptLehninger_Chapter 17_Fatty acid Oxid.ppt
Lehninger_Chapter 17_Fatty acid Oxid.ppt
 
World Water Day 22 March 2024 - kiyorndlab
World Water Day 22 March 2024 - kiyorndlabWorld Water Day 22 March 2024 - kiyorndlab
World Water Day 22 March 2024 - kiyorndlab
 
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
Applying Cheminformatics to Develop a Structure Searchable Database of Analyt...
 
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptxQ3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
Q3W4part1-SSSSSSSSSSSSSSSSSSSSSSSSCI.pptx
 
geometric quantization on coadjoint orbits
geometric quantization on coadjoint orbitsgeometric quantization on coadjoint orbits
geometric quantization on coadjoint orbits
 

PREFORMULATION

  • 1. PREFORMULATION PREPARED BY:- PANDYA DEEP R. M.PHARM SEM-1 PHARMACEUTICS Guided By:- Mr. Keyur Patel Pharmaceutics Department K.B.Raval College Of Pharmacy 1
  • 2. Incompatibility- general aspects ►inactivation of drug through either decomposition or loss of drug by its conversion to a less favorable physical or chemical form. ►It affects safety, therapeutic efficacy, appearance or elegance. ►When we mix two or more API and / or excipient with each other & if they are antagonistic & affect adversely the safety, therapeutic efficacy, appearance or elegance then they are said to be incompatible. 2
  • 3. Importance of Drug Excipient Compatibility Study:-  Stability of the dosage form can be maximized.  It helps to avoid the surprise problems.  DECS data is essential for IND (investigational new drug ) submission.  Determine a list of excipients that can be used in final dosage form. 3
  • 4.  Aspects of above tests are- ►Identification of compatible excipients for a formulation ►Identification of stable storage conditions for drug in solid or liquid state. 4
  • 5. Types Of Incompatibility  Physical incompatibility:- It involves the change in the physical form of the formulation which involves color changes, liquefaction, phase separation or immiscibility.  Chemical incompatibility:- It involves undesirable change in formulation which is due to formation of new chemical comp. with undesirable activity or our formulation undergoes hydrolysis, oxidation, reduction, precipitation, decarboxylation, racemization.  Therapeutic incompatibility:- It is type of in vivo compatibility. 5
  • 6.  Solid state reactions: much slower and difficult to interpret.  Liquid state reactions: easier to detect - Acc. to Stability Guidelines by FDA following conditions should be evaluated for solutions or suspensions . 6
  • 7.  FOR SOLID STATE REACTIONS: SampleA: -mixture of drug and excipient SampleB: -SampleA+ 5% moisture SampleC: -Drug itself without excipients 7
  • 8.  All the samples of drug-excipient blends are kept for 1-3 weeks at specified storage conditions.  Then sample is physically observed .  It is then assayed by TLC or HPLC or DSC.  Whenever feasible, the degradation product are identified by MASS SPECTROSCOPY, NMR or other relevant analytical techniques. 8
  • 9. FOR LIQUID STATE REACTIONS:  Place the drug in the solution of additives.  Both flint and amber vials are used.  This will provide information about Susceptibility to oxidation. – Susceptibility to light exposure. – Susceptibility to heavy metals.  In case of oral liquids, compatibility with ethanol, glycerin ,sucrose, preservatives and buffers are usually carried out. 9
  • 10. Technique Name  1) TMA a) DSC b) DTA  2) ASS  3) FT-IR  4) DRS  5) Chromatography  6) Radiolabelled Techniques  7) Vapour Pressure osmometry  8) Flourescence Spectroscopy 10
  • 11. 11
  • 12. KNOWN INCOMPATIBILITIES Functional group Incompatibility Type of reaction Primary amine Mono & Di-saccharides Amine-Aldehyde & Amine-Acetal Ester, Lactone Basic component Ring opening, Ester base hydrolysis Aldehyde Amine, Carbohydrate Aldehyde-Amine, Schiff base Or Glycosylamine formation Carboxyl Base Salt formation Alcohol Oxygen Oxidation to Aldehyde & Ketones Sulfhydryl Oxygen Dimerization Phenol Metal Complexation Gelatin- Capsule Shell Cationic Surfactant Denaturation 12
  • 13. 1) INTRODUCTION Thermal method of analysis are group of techniques in which changes in physical and /or chemical properties of a substance are measured as a function of temperature, while substance is subjected to controlled temp programme. 13
  • 14.  Thermal analytical methods can measure the following physical properties,  a) WEIGHT LOSS ON DRYING  b) ENTHALPY  c) TEMP  d) GAS EVOLUTION  e) ELECTRICAL CONDUCTIVITY  f) OPTICAL CHARACTERISTIC  g) MAGNETIC PROPERTIES  h) CHANGES IN FORM IN DIMENSION  i) VISCOELASTIC PROPERTIES OF SUBSTANCE 14
  • 15.  They are unique methods in the field of polymer analysis & of high value for a solid state analysis.  They finds wide application in  Detection of impurity  Determination of moisture content in any drug substance or any excipient  Study of polymorphism  Characterization of hydrates & solvates  Degree of Crystallinity  Study of phase diagram  Drug excipient compatibility study  Study of complexation 15
  • 16. Physical properties Name of technique Instrument used 1) MASS A)THERMOGRAVIMETRY THERMO BALANCE B)EVOLVED GAS ANALYSIS EVOLVED GAS DETECTOR 2) TEMP DIFFERENTIAL THERMAL ANALYSIS (DTA) DTA APPARATUS 3) ENTHALPY DIFFERENTIAL SCANNING CALORIMETRY (DSC) DIFFERENTIAL CALORIMETER 4) MECHANICAL PROPERTIES (DIMENTION,VISCOELASTIC PROPERTIES) A)THERMO MECHANICAL ANALYSIS TMA APPRATUS B)THERMODILATOMETRY DILATOMETER 6) OPTICAL CHARACTERISTIC THERMOPTOMETRY 7) MAGNETIC SUSCEPTIBILITY THERMOMAGNETOMETRY 8) ELECTRICAL RESISTANCE OR CONDUCTION THERMOELECTROMETRY 16
  • 17.  PRINCIPLE: TG is a technique in which a change in the weight of a substance is recorded as a function of temperature or time.  Instrument: Instrument used for thermogravimetry is thermobalance → Major components of a Thermobalance  Sample container ,usually shallow platinum crucible.  Furnace Assembly  Automatic recording Balance(Micro balance 17
  • 18.  Factors affecting Thermogravimetry analysis are  Heating rate  atmosphere  Sample characteristic 18
  • 19. DATA RECORDED IN FORM OF CURVE KNOWN AS THERMOGRAM. THERMOGRAMS CAN BE DIVIDED INTO TWO PORTIONS: 1) HORIZONTAL PORTION: INDICATE REGION WHERE THERE IS NO WEIGHT LOSS. 2) CURVED PORTION: INDICATE REGIONS OF WEIGHT LOSS. 19
  • 20.  PRINCIPLE: It is a technique in which the energy necessary to establish a zero temp difference between the sample & reference material is measured as a function of temp.  Endothermic reaction. E.g. Melting, boiling, sublimation, vaporization, desolvation.  Exothermic reaction: E.g crystallization, degradation, polymerization. 20
  • 21. DIFFERENTIAL SCANNING CALORIMETRY (DSC)  DSC is widely used to measure glass transition temp & characterization of polymer.  Glass Transition temp(Tg): Temp at which an amorphous polymer or an amorphous part of crystalline polymer goes from hard ,brittle state to soft, 21
  • 22. C) DIFFERENTIAL THERMAL ANALYSIS (DTA)  PRINCIPLE: A Technique in which the temperature difference between a substance & a reference material is measured as a function of temperature, while the substance & reference are subjected to a controlled temperature programme.  The Difference in temperature is called as Differential temp(∆t) is plotted against temperature or a function of time.  Physical changes usually result in Endothermic peak ,whereas chemical reactions those of an oxidative nature are exothermic. 22
  • 23. MAJOR APPLICATION OF THERMAL ANALYSIS IN PREFORMULATION  A) Characterization of hydrates and solvates .  B) study of polymer  C) Detection of impurity.  D) Prediction of stability of drug  E) Degree of crystallinity  F). Compatibility study of drug with excipient.  G) Study of complexes & inclusion compounds. 23
  • 24. MINOR APPLICATIONS  - DSC is a valuable tool in choice of suppository base.  - In study of polymer composition ,miscibility & individual characterization. - Study of tablet coating - Determinations of melting point. etc - Determination of moisture content in drug. - Checking technological quality grade of disintegrate. - Study of solid drug dispersion. - Determination of drying temp. for different excipients. 24
  • 25. LIMITATIONS OF THERMAL ANALYSIS  1) low sensitivity for transitions involving small energies.  2) The interpretation of the curves & DSC studies should always Include several conditions & replicate.  3) Impurity consisting of molecules of same size, shape, & character as those of the major component are not detected by DSC, Because these impurity fit into the matrix of the major component without disruption of lattice forming solid solution or inclusion ,such impurity are not detected by DSC.  4) TGA used to studies hydrates & moisture study is not always reliable. 25
  • 26. X-RAY DIFFRACTION IN PREFORMULATION  METHOD:- Principle:- «- An x-ray irradiation produce a highly specific diffraction pattern from a crystal of material.  An X-ray diffraction pattern from the crystal is formed a series of dots of varying intensity with fixed angular & recorded on photographic film. «-  It is powerful tool for particle size analysis. 26
  • 27. FTIR TECHNIQUE:  It has been used to quantify binary mixtures of polymorphs.  In identification of polymorphs , only solid samples (as mineral oil mulls & KBr pellets) can be used .  In solutions polymorphs of a compound have identical spectra .  Techniques for solid state stability studies:  Advantages: - Rapid. • TECHNIQUE IS QUALITATIVE & QUANTITATIVE. 27
  • 28. (1) INTRODUCTION  Impurities in pharmaceuticals are the unwanted chemicals that remain with active pharmaceutical ingredients (APIs),or develop during formulation, or upon aging of APIs and formulated APIs to medicines.  Webster‘s dictionary defines impurity are something that is impure or makes something else impure. .  ►Organic volatile impurities OVIs are generally solvents used in the synthesis or during the formulation of the drug product. 28
  • 29.  a) impurities associated in with APIs  b) impurities that forms are created during formulation & or with aging or that are related to formulated forms.  According to ICH guidelines impurities associated with APIs are classified in to following categories- (a)Organic impurities (b)Inorganic impurities (c)Residual solvents (d)Other materials 29
  • 31.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENT FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE  ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES:  GUIDELINE FOR RESIDUAL SOLVENTS Q3C(R3) Impurities: Guideline for Residual Solvents Q3C  Impurities: Guideline for Residual Solvents (Maintenance) PDE for Tetrahydrofuran (in Q3C(R3)) Q3C(M) 31
  • 32. ICH HARMONISED TRIPARTITE GUIDELINE  GENERAL PRINCIPLES Classification of Residual Solvents by Risk Assessment  The term "tolerable daily intake" (TDI) is used by the International Program on Chemical Safety (IPCS) to describe exposure limits of toxic chemicals and "acceptable daily intake"(ADI) is used by the World Health Organization (WHO) and other national and international health authorities and institutes. The new term "permitted daily exposure" (PDE) is defined in the present guideline as a pharmaceutically acceptable intake of residual solvents to avoid confusion of differing values for ADI's of the same substance.  Residual solvents assessed in this guideline are listed in Appendix 1 by common names and structures. They were evaluated for their possible risk to human health and placed into one of three classes as follows: 32
  • 33. CLASSES EVALUATED ON THE BASES OF THEIR POSSIBLE RISK  Class 1 solvents: Solvents to be avoided carcinogens and environmental e.g.,Benzene, Carben tetrachloride, 1,1-Dichlorobenzene, etc  Class 2 solvents: Solvents to be limited Non-genotoxic animal carcinogens or possible causative agents of other irreversible toxicity such as neurotoxicity or teratogenicity. e.g.,Acetonitrile,Chlorobenzene,Chloroform,Cyclohexane  Class 3 solvents: Solvents with low toxic potential Solvents with low toxic potential to man;Class 3 solvents have PDEs of 50 mg or more per day. e.g.,Acetone, Anisol, 1-Butanol, Cumene, Ethyl ether,etc .  Class4 solvents: Solvents for which no toxicological data have been found Sovents for which no adequate toxicological have been found. e.g.,1,1-Dietoxypropane,Trifluroacetic acid,Ethyl acetate,etc. 33
  • 34. METHODS FOR ESTABLISHING EXPOSURE LIMITS:-  The Gaylor-Kodell method of risk assessment, is appropriate for Class 1 carcinogenic solvents. Only in cases where reliable carcinogenicity data are available should extrapolation by the use of mathematical models be applied to setting exposure limits. Exposure limits for Class 1 solvents could be determined with the use of a large safety factor  Acceptable exposure levels in this guideline for Class 2 solvents were established by calculation of PDE values. PDE is derived from the no-observed-effect level (NOEL), or the lowest-observed effect level (LOEL) in the most relevant animal study as follows:  PDE = NOEL x Weight Adjustment F1x F2 x F3 x F4 x F5  The PDE is derived preferably from a NOEL. If no NOEL is obtained, the LOEL may be used. 34
  • 35. METHODS FOR ESTABLISHING EXPOSURE LIMITS:-  F1 = A factor to account for extrapolation between species, F1 takes into account the comparative surface area: body weight ratios for the species concerned and for man.  F2 = A factor of 10 to account for variability between individuals.  F3 = A variable factor to account for toxicity studies of short-term exposure  F4 = A factor that may be applied in cases of severe toxicity, e.g. non-genotoxic carcinogenicity, neurotoxicity or teratogenicity.  F5 = A variable factor that may be applied if the no-effect level was not established 35
  • 36. LIMITS OF RESIDUAL SOLVENTS :-  Solvent Concentration Limit (ppm)  Benzene 2  Carbon tetrachloride 4  1,2-Dichloroethane 5  1,1-Dichloroethene 8  1,1,1-Trichloroethane 1500 Solvents to Be Avoided:- 36
  • 37. LIMITS OF RESIDUAL SOLVENTS Class 2 solvents in pharmaceutical products. .  SOLVENT CONCENTRATION LIMIT (PPM)  Acetonitrile 410  Chlorobenzene 360 Chloroform 60  Cyclohexane 3880  1,2-Dichloroethene 1870 Dichloromethane 600  N,N-Dimethylacetamide 1090  N,N-Dimethylformamide 880  Ethylene glycol 620  Formamide 220  Hexane 290  Methanol 3000 37
  • 38. LIMITS OF RESIDUAL SOLVENTS  Acetic acid, Heptane, Acetone,  Isobutyl acetate, Anisole, Isopropyl acetate,  1-Butanol, Methyl acetate, 2-Butanol,  3-Methyl-1-butanol, Butyl acetate, Methylethyl ketone,  tert-Butylmethyl ether, Methylisobutyl ketone, Cumene,  2-Methyl-1-propanol, Dimethylsulfoxide, Pentane,  Ethanol, 1-Pentanol, Ethyl acetate, 1-Propanol, Ethyl ether, 2-Propanol, Ethyl formate, Propyl acetate Formic acid, Class 3 solvents which should be limited by GMP or other quality based requirements. 38
  • 39. LIMITS OF RESIDUAL SOLVENTS Solvents for which no adequate toxicological data was found are given below. o 1,1-Diethoxypropane, o Methylisopropyl ketone, o 1,1-Dimethoxymethane, o Methyltetrahydrofuran 2, o 2-Dimethoxypropane, o Petroleum ether, o Isooctane, o Trichloroacetic acid, o Isopropyl ether 39
  • 40. AS PER U.S. PHARMACOPOEIA REGULATORY LIMITS  Organic volatile USP/NF limits USP/NF 2003 impurities before 2003 (ppm) limits (ppm) Benzene 100 Not specific o Chloroform 50 60 o 1,4-Dioxane 100 380  Methylene chloride 500 600  Trichloroethylene 100 80 40
  • 41. PREFORMULATION STUDY OF BIOTECHNOLOGICAL PRODUCTS  INTRODUCTION TO BIOTECHNOLOGY  "Biotechnology means any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use." 41
  • 42. PHYSICO-CHEMICAL PROPERTIES OF BIOTECHNOLOGICAL PRODUCTS  1. Purity, Impurities and Contaminants  2. Structural Characterization  3. Conformation Study  4. Physical Characterization 42
  • 43. 4. PHYSICAL CHARACTERIZATION OF BIOTECHNOLOGICAL PRODUCTS  1 SOLID STATE PROPERTIES. 1 Crystallinity 2 Hygroscopicity 3 Molecular weight 4 Thermal Denaturation temperature 5 Extinction coefficient.  2 SOLUTION PHASE PROPERTIES 1 Ionic Strength 2 pH 3 Adsorption 4 Solubility 5 Surface interaction 43
  • 44. 1. PURITY, IMPURITIES AND CONTAMINANTS  The impurities in the products are:  Process related cell-culture media, host cell proteins, DNA, monoclonal antibodies  Product related product during the manufacture &/or storage 44
  • 45. PURITY DETERMINATION TECHNIQUE  Protein based product  SDS-PAGE ,HPLC ,Immunological approaches like immunoassay  Amino acid analysis ,N-terminal sequencing ,peptide mapping  Pyrogen detection  Rabbit pyrogen test (exogenous pyrogen) and LAL Test(endotoxins)  DNA  DNA Hybridization studies(dot-blot assay)utilizes radiolabel led DNA probes  Microbial  virus –specific DNA probes , immunoassays. 45
  • 46. 2.STRUCTURAL CHARACTERIZATION  Protein architecture are typically described in terms of primary ,secondary ,tertiary & quaternary & the order of stability is from primary>>>quaternary.  Protein structure is determined by following techniques, SDS-gel electrophoresis ,HPLC (mainly RP-HPLC) ,Amino acid analysis ,N- terminal sequencing etc 46
  • 47. 3. CONFORMATION  A protein’s conformation is the most elusive of its physical properties in that it may be the most difficult not only to ascertain but to maintain.  One must establish the other conformational forms present have no undesirable chemical, physical and biological effects.  It can be determined by the following technique ,X-ray diffraction ( to study 3Dprotein conformation ,Circular dichrosim ,Peptide mapping ,N-terminal sequencing or amino acid to determine amino acid sequence. ,Spectroscopic techniques ( UV,IR, Raman, Fluorescence) 47
  • 48. 4. PHYSICAL CHARACTERIZATION SOLID STATE PROPERTIES  Crystallinity:  Lack of crystallinity is characterized by the low intensity peaks or broad bands in the  POWDER X-ray pattern.  Other methods used are X-ray Diffraction pattern, Solid state NMR (SS-NMR),Differential scanning calorimetry ( DSC), Thermo gravimetric analysis (TGA).  Hygroscopicity:  The changing environmental conditions can affect the stability of the hygroscopic products .The estimation of water content done by the HPLC method 48
  • 49. 4. PHYSICAL CHARACTERIZATION Molecular weight:  The molecular size of peptides and proteins are 1 to 3 orders of magnitude larger than that of conventional drug molecules, is a major factor limiting their diffusion across the biological membranes.  Biopharmaceuticals molecular weight ranges from 600 to more than 10,000daltons in their non- aggregated state  Larger the size ,lower the permeation across biological membranes g.i.t, ocular epithelium ,stratum corneum considered as impermeable barriers to the permeation to the latter.  Molecular size also restricts diffusion of the biopharmaceutical across the polymeric barriers, used in the fabrication of proteins and peptides delivery systems. 49
  • 50. 4. PHYSICAL CHARACTERIZATION Extinction coefficient (molar absorptivity):  For quantification purpose, it is desirable to measure at a particular UV-VIS wavelength for the measurement of the protein content. Thermal denaturation temperature:  Most proteins can be reversibly denatured with an increase in temperature and continued increase can result in irreversible denaturation (seen in enzymes).  Also in some case, protein unfolds and refolds into new structure different then original native one.  FREEZE –DRYING of proteins in presence of appropriate buffer excipients can minimize the problem 50
  • 51. 4. PHYSICAL CHARACTERIZATION SOLUTION PHASE PROPERTIES Adsorption:  In the case of where adsorption is due to ionic interaction of the peptide with the silanol groups on the glass surface, can be prevented by silylating the glass (flasks, syringes,etc) with organosilanes such as Prosil 28. Solubility and charge:  The solubility of a protein is a useful indicator of changes that may occur in the protein conformation  If a protein denatures, more hydrophobic groups may be exposed to the aqueous phase from the interior of the protein. 51
  • 52. 4. PHYSICAL CHARACTERIZATION PH:  Ph has profound effect on protein stability ,folding and rates of reaction which chemically alter the amino acid residues  In some cases it may be possible to formulate the protein under conditions where chemical modifications and proteolysis are minimized as much as possible while maintaining the protein in misfolded conformation which is readily and rapidly refolded to “native” form upon administration. Ionic strength:  The concentration of counter ions is known to be an important property in mediating electrostatic interactions in molecule, and have large effect on stability of a protein as well as its solubility.  For example: Guanidium HCl is a strong naturant of protein where as Guanidium sulphate at equivalent concentration can stabilize proteins. 52
  • 53. BIOLOGICAL CHARACTERIZATION  Validated biological assays should be performed at the preformulation stage to assess the biological activity.  For the complex molecules, the physio-chemical information may be extensive but unable to confirm the higher order structures, a biologic activity with a specific quantitative measure.  Radio receptor assays (RIA) may be used to relate binding of a protein hormone to a cellular receptor and may be used to asses activity protein fragments, produced by the enzymatic degradation  Immunogenicity is ability to induce the formation of antibodies when combined with antigenicity is the ability to react with specific antibodies can potentially result in the development of hypersensitivity reactions.  Techniques for minimizing the immunogenicity (considered at the preformulation stage ) 1. Cloned peptides and proteins 2. Conjugation of peptides and proteins to low molecular weight compounds 3. Conjugation of peptides and proteins to various polymers such as dextran, albumin, dl- amino acids, poly vinyl pyrrolidone, polyethylene glycol,etc 53
  • 54. ORAL DELIVERY OF INSULIN BY CONJUGATION WITH VITAMIN B12  Limitation of oral delivery of insulin: 1. Proteolysis in GIT 2. Absorption at intestinal entrocyte  To overcome this problem, we decided to use the dietary uptake pathway of vitamin B12. Mammals have an active transport mechanism in the GIT for the absorption and the cellular uptake of relatively large vitamin B12. 54
  • 55. DEGRADATION PROCESSES OF PROTEIN PHARMACEUTICALS  PHYSICAL INSTABILITY 1 Denaturation 2 Surface adsorption 3 Aggregation 4 Precipitation.  CHEMICAL INSTABILITY 1 Hydrolysis 1.1 Deamidation 1.2 Intramolecular aminolysis 1.3 Transpeptidation 2 Oxidation 3 Racemization 4 β-elimination 55
  • 56. METHODS TO IMPROVE PHYSICAL STABILITY  Additives such as metal ions ,polyalcohol ,surfactants ,reducing agents ,chelating agents and other proteins ,amino acids ,fatty acids and phospholipids  Specific ion binding sites can be introduced on protein molecules in relation to the aggregation and precipitation. eg salts  Both ionic and non-ionic surfactants can stabilize proteins by preventing adsorption of proteins at interfaces  At low concentration in aqueous solutions ,polyhydric alcohol such as glycerol by selective salvation .(excluding the water molecules) 56
  • 57. METHODS TO IMPROVE CHEMICAL STABILITY:  1. Chemical modification of protein molecules: Synthetic polymers like PEG and Polyoxyethylene can be coupled to protein molecules chemically to enhance the chemical stability. Comparatively, lipids coupled with Insulin can increase the absorption of Insulin and hence can increase the activity.  2 Site directed mutagenesis: This technique creates specific mutations that alter the amino acid sequence of proteins and create new proteins. 57
  • 58. METHODS TO IMPROVE CHEMICAL STABILITY:  3. Appropriate choice of conditions:  pH,  temperature,  preservative  ionic strength. 58
  • 59. FORMULATION APPROACHES TO PROTEIN STABILIZATION Protein stabilization in solution using additives:  Concentration of salts has profound effect on protein solution and aggregation.  Non ionic surfactants like, polysorbate 80 inhibits protein aggregation because of greater tendency of surfactant molecule to align themselves at the liquid-air interface, so, excluding the proteins from interface and inhibiting surface denaturation.  Use of cyclodextrin or 2-Hydroxy propyl--cyclodextrin solubilizes ovine growth hormone and prevents shaking induced precipitation. 59
  • 60. FORMULATION APPROACHES TO PROTEIN STABILIZATION 2. Protein stabilization in the dried solid state: Lyophilization and spray drying used to dehydrate heat sensitive molecules and thereby inhibit the degradative reactions that may be observed when proteins are formulated in solution  Mechanism for Stabilization of Dried Proteins:  Binding of additives to the dried protein to act as a “water substitute” after removal of hydration shell. As water substitutes, sugars such as lactose can serve to partially satisfy Hydrogen bonding requirements of polar groups in dried proteins. 60
  • 61. FORMULATION APPROACHES TO PROTEIN STABILIZATION  Lyophilization and protein formulation development:  It is characterized by two primary concerns:  1 Excipient selection to optimize long term stability of protein in the dried state.  2. Effect of excipient on processing parameters of Lyophilization cycle such as maximum and minimum drying temperature and cycle length and on the appearance of the lyophilized powder cake.  Freezing causes gradual concentration of solutes surrounding the protein molecule s water is removed by the phase change.  Spray drying of protein pharmaceuticals:  It is alternative to freeze drying proteins as a process capable of drying thermally labile materials.  The particles are dried in the air stream in seconds, owing to high surface area contact with drying gas.  Its major advantage over Lyophilization is particle size and shape of final dried powder. 61
  • 62. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT  1 Preamble  The applicant should develop the proper supporting stability data for biotechnological product and consider many external conditions that can affect the product's potency, purity, and quality.  The purpose of this document is to give guidance to applicants regarding the type of stability studies that should be provided in support of marketing applications. 62
  • 63. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT  2 Scope of the annex  Stability Testing of New Drug Substances and Products'' applies to well-characterized proteins and polypeptides, their derivatives and products of which they are components, and which are isolated from tissues, body fluids, cell cultures, or produced using recombinant deoxyribonucleic acid (r-DNA) technology.  The document does not cover antibiotics, allergenic extracts, heparins, vitamins, whole blood, or cellular blood components. 63
  • 64. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT 3 Selection of Batches  3.1 Drug Substance (Bulk Material) Where bulk material is to be stored after manufacture, but before formulation and final manufacturing, stability data should be provided on at least three batches for which manufacture and storage are representative of the manufacturing scale of production.  3.2 Sample Selection Where one product is distributed in batches differing in fill volume (e.g., 1 milliliter (mL), 2 mL, or 10 mL), unit age (e.g., 10 units, 20 units, or 50 units), or mass (e.g., 1 milligram (mg), 2mg, or 5 mg), samples to be entered into the stability program may be selected on the basis of a matrix system and/or by bracketing. 64
  • 65. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT 4. Stability-Indicating Profile  Consequently, the manufacturer should propose a stability- indicating profile that provides assurance that changes in the identity, purity, and potency of the product will be detected.  At the time of submission, applicants should have validated the methods that comprise the stability-indicating profile, and the data should be available for review.  The determination of which tests should be included will be product-specific.  4.1 Protocol  The protocol should include all necessary information that demonstrates the stability of the biotechnological product throughout the proposed expiration dating period including, for example, well-defined specifications and test intervals. 65
  • 66. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT  4.2 Potency  For the purpose of stability testing of the products described in this guideline, potency is the specific ability or capacity of a product to achieve its intended effect and is determined by a suitable in vivo or in vitro quantitative method.  For that purpose, a reference material calibrated directly or indirectly against the corresponding national or international reference material should be included in the assay. 66
  • 67. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT 5. Storage Conditions Temperature  As most finished biotechnological products need precisely defined storage temperatures, the storage conditions for the real-time/real-temperature stability studies may be confined to the proposed storage temperature. Humidity  Biotechnological products are generally distributed in containers protecting them against humidity. Therefore, where it can be demonstrated that the proposed containers (and conditions of storage) afford sufficient protection against high and low humidity, stability tests at different relative humidity can usually be omitted. 67
  • 68. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT Accelerated and Stress Conditions  The expiration dating should be based on real- time/real-temperature data. However it is strongly suggested that studies be conducted on the drug substance under accelerated and stress conditions.  Also useful in determining whether accidental exposures to conditions other than those proposed (e.g., during transportation) are deleterious to the product and also for evaluating which specific test parameters may be the best indicators of product stability.  Light 68
  • 69. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT Container/Closure  Stability studies should include samples maintained in the inverted or horizontal position (i.e., in contact with the closure), as well as in the upright position, to determine the effects of the closure on product quality.  The applicant should demonstrate that the closure used with a multiple-dose vial is capable of withstanding the conditions of repeated insertions and withdrawals so that the product retains its full potency, purity, and quality for the maximum period specified in the instructions-for-use on containers, packages, and/or package inserts. Stability after Reconstitution of Freeze-Dried Product  The stability of freeze-dried products after their reconstitution should be demonstrated for the conditions and the maximum storage period specified on containers, packages, and/or package inserts. 69
  • 70. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT 6. Testing Frequency  The shelf lives of biotechnological products may vary from days to several years.  With only a few exceptions, however, the shelf lives for existing products and potential future products will be within the range of 0.5 to 5 years.  When shelf lives of 1 year or less are proposed, the real-time stability studies should be conducted monthly for the first 3 months and at 3 month intervals thereafter.  For products with proposed shelf lives of greater than 1 year, the studies should be conducted every 3 months during the first year of storage, every 6 months during the second year, and year of storage, every 6 months during the second year, and annually thereafter. 70
  • 71. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT 7. Specification:  Although biotechnological products may be subject to significant losses of activity, physicochemical changes, or degradation during storage, international and national regulations have provided little guidance with respect to distinct release and end of shelf life specifications.  Recommendations for maximum acceptable losses of activity, limits for physicochemical changes, or degradation during the proposed shelf life have not been developed for individual types or groups of biotechnological products but are considered on a case-by-case basis. 71
  • 72. GUIDELINES ON THE STABILITY OF THE BIOTECHNOLOGICAL PRODUCT 8. Labeling  For most biotechnological drug substances and drug products, precisely defined storage temperatures are recommended.  Specific recommendations should be stated, particularly for drug substances and drug products that cannot tolerate freezing.  These conditions, and where appropriate, recommendations for protection against light and/or humidity, should appear on containers, packages, and/or package inserts. 72
  • 73. QUE.  a) A Pharmacist wants to develop a transdermal patch of hormone. ,What test should be carried out in order to ascertain drug-excipient incompatibility? Give outline and significance of each test.  Discuss the considerations of OVIs in preform  Give an applications of Differential scanning calorimetry and FTIR in preformulation studyulation study.  Why OVIs are considered in preformulation study?  How the preformulation studies for biotechnologically derived products are carried out? 73
  • 74. 74